Health Discovery Corporation Applauds American Cancer Society’s Decision Against The Use Of The PSA For Routine Prostate Cancer Screening
Health Discovery Corporation (OTCBB: HDVY) announced today that it
supports the American Cancer Society’s decision to issue new guidelines
in the face of substantial data found in the largest prostate cancer
Health Discovery Corporation (OTCBB: HDVY) announced today that it supports the American Cancer Society’s decision to issue new guidelines in the face of substantial data found in the largest prostate cancer studies ever conducted that were recently published in the New England Journal of Medicine in 2009. These published studies warned that using PSA to screen for prostate cancer doesn't necessarily save lives, and noted any benefits can come at a high price including over-diagnosis of prostate cancer leading to unnecessary treatments which can result in impotence and incontinence which are potentially devastating and life changing side effects in these men. Health Discovery Corporation’s Science Advisory Board member, Dr. Thomas Stamey, the founder and former chairman of the Department of Urology at Stanford University Medical Center, and a world renowned leader in prostate cancer published in the Journal of Urology several years ago: “The era of the PSA is over.” At the time of Dr. Stamey's landmark publication, Health Discovery Corporation began the development of its new gene-based molecular diagnostic test for prostate cancer. “Health Discovery Corporation’s new, urine-based 4-gene prostate cancer test which has been shown to have a 90% Sensitivity (for finding clinically significant, grade 3 or higher prostate cancer cells) and a 97% Specificity (for finding non-cancerous cells) was recently published in the peer-reviewed publication UroToday International,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We are very pleased that the American Cancer Society is now warning men and their doctors about the risks of using the PSA test for routine prostate cancer screening," said Dr. Barnhill. Health Discovery Corporation's new urine-based 4-gene prostate cancer test is licensed on a royalty based, worldwide co-exclusive basis to Quest Diagnostics Incorporated (NYSE: DGX) and Abbott (NYSE: ABT). The Associate Press released a story today on the American Cancer Society’s new guidelines titled, “Cancer society stops urging docs to offer PSA test,” by Mike Stobbe, AP Medical Writer, and Stephanie Nano contributed to the story.